Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

ONO PHARMACEUTICAL CO., LTD. (4528)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

ONO PHARMACEUTICAL : Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Cancer Patients Published in New England Journal of Medicine (NEJM) and Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) (94.2KB)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/04/2012 | 04:15am CEST

June 4th, 2012

ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Cancer Patients Published in New England Journal of Medicine (NEJM) and Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)

Bristol-Myers Squibb Company (hereinafter referred to as "BMS") announced the results from Phase 1 study in patients with non-small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC) to be published in New England Journal of Medicine (NEJM) and presented at 48th

Annual Meeting of the American Society of Clinical Oncology (ASCO), on June 2nd (US time).

ONO-4538/BMS-936558, a fully human anti-PD-1 antibody, is an investigational cancer immunotherapy generated under a research collaboration entered into in May 2005 between Ono Pharmaceutical Co., Ltd. (hereinafter referred to as "Ono") and Medarex, Inc. When Medarex, Inc. was acquired by BMS in

2009, it also granted BMS its rights to develop and commercialize the anti-PD-1 antibody in North America. Through the collaboration agreement entered into in September 2011 between Ono and BMS, Ono granted BMS exclusive rights to develop and commercialize ONO-4538/BMS-936558 in the rest of the world, except in Japan, Korea and Taiwan where Ono has retained all rights to develop and commercialize the compound.

BMS is conducting a Phase 2 study in RCC in North America and Europe, and plans to initiate registrational studies for anti-PD-1 this year in NSCLC and RCC, and late 2012, early 2013 for metastatic melanoma. On the other hand, Ono is conducting a Phase 2 study in metastatic melanoma in Japan, and plans to initiate clinical studies in RCC and NSCLC, taking account of the development status in United States and Europe.

Attached from the following page is the press release made by BMS for your information.

Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1

Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONO PHARMACEUTICAL CO., LT
04/19ONO PHARMACEUTICAL : U.S. Food and Drug Administration Accepts Supplemental Biol..
PU
04/18ONO PHARMACEUTICAL : U.S. Food and Drug Administration Approves Opdivo® (nivolum..
PU
04/17ONO PHARMACEUTICAL : Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of..
PU
04/17ONO PHARMACEUTICAL : In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustaine..
PU
04/16ONO PHARMACEUTICAL : Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Sup..
PU
04/12ONO PHARMACEUTICAL : Patent Application Titled "Method for Extracting Lead Compo..
AQ
04/12ONO PHARMACEUTICAL : Karyopharm's Selinexor Receives Fast Track Designation from..
PU
04/05ONO PHARMACEUTICAL : Patent Application Titled "Process for Producing Purinone D..
AQ
04/05ONO PHARMACEUTICAL : Researchers Submit Patent Application, "Method for Producin..
AQ
03/28ONO PHARMACEUTICAL CO., LTD. : Ex-dividend day for for final dividend
FA
More news
News from SeekingAlpha
03/23Alzheon Files To Raise $80 Million In U.S. IPO 
03/14Ono Pharma exercises option for Merus Biclonics technology for autoimmune bis.. 
2017Ono Pharmaceutical Needs To Reinvest Its Windfall 
2017YOUR DAILY PHARMA SCOOP : Axovant's Promised Upside, Gilead's Whistleblower Trou.. 
2017Only Bristol Bucks Big Pharma's Drive For External Reliance 
Financials ( JPY)
Sales 2018 260 B
EBIT 2018 -
Net income 2018 46 364 M
Finance 2018 111 B
Yield 2018 1,89%
P/E ratio 2018 28,02
P/E ratio 2019 25,83
EV / Sales 2018 4,75x
EV / Sales 2019 4,41x
Capitalization 1 349 B
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Technical analysis trends ONO PHARMACEUTICAL CO., LT
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 3 187  JPY
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director & Executive Vice President
Isao Ono Director & Managing Executive Officer
Kei Sano Director & Senior Executive Officer
Sector and Competitors